#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3432	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2152	306.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1584	1584	C	323	C	215	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5788	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3731	306.9	0	.	n	.	0	T695C	SNP	695	695	T	1111	1111	C	400	C,A	275,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5788	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3731	306.9	0	.	n	.	0	A1638G	SNP	1638	1638	A	2054	2054	G	290	G,A	153,53	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5788	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3731	306.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2387	2387	C	338	C	243	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5788	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3731	306.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2461	2461	A	392	A	272	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	5788	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3731	306.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3013	3013	C	411	C	289	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	974	folP	855	855	100.0	folP.l15.c4.ctg.1	1929	98.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1203	1205	AGC	180;180;181	A;G;C	125;127;129	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	15	1622	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3454	89.5	1	SNP	p	S91F	1	.	.	271	273	TTC	605	607	TTC	125;125;125	T;T;C,T	85;84;82,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	15	1622	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3454	89.5	1	SNP	p	D95G	1	.	.	283	285	GGC	617	619	GGC	132;132;133	G;G;C	88;88;88	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	15	1622	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3454	89.5	1	SNP	p	G95N	0	.	.	283	285	GGC	617	619	GGC	132;132;133	G;G;C	88;88;88	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	15	1622	gyrA	2751	93	100.0	gyrA.l6.c4.ctg.2	495	1.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	278	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1512	38.8	1	SNP	p	G45D	0	.	.	133	135	GGC	738	740	GGC	102;102;102	G;G;C	68;66;67	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	264	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1172	42.0	0	.	n	.	0	A197.	DEL	197	197	A	708	708	A	101	A	68	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2771	126.8	1	SNP	p	D86N	0	.	.	256	258	GAC	430	432	GAC	187;188;192	G;A;C	119;113;123	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2771	126.8	1	SNP	p	R87W	0	.	.	259	261	CGT	433	435	CGT	192;194;196	C;G;T	126;119;123	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2771	126.8	1	SNP	p	S87R	1	.	.	259	261	CGT	433	435	CGT	192;194;196	C;G;T	126;119;123	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2771	126.8	1	SNP	p	R87I	0	.	.	259	261	CGT	433	435	CGT	192;194;196	C;G;T	126;119;123	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1856	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2771	126.8	1	SNP	p	S88P	0	.	.	262	264	TCC	436	438	TCC	196;196;196	T;C,A;C	127;128,1;130	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2198	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2902	149.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1551	1553	GGC	137;142;142	G;G;C	96;96;96	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1328	1330	GCC	129;129;129	G;C;C	92;92;92	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1331	1333	ATG	130;130;130	A;T;G,T	92;92;91,1	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1343	1345	ACC	129;129;130	A;C;C	93;93;93	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1343	1345	ACC	129;129;130	A;C;C	93;93;93	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1844	1846	ACC	165;165;164	A;C,A;C	113;109,1;111	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1898	1900	GCG	150;150;151	G;C;G	99;95;99	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1898	1900	GCG	150;150;151	G;C;G	99;95;99	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2021	2023	GGT	123;123;120	G,A;G,T;T,G	86,1;87,1;83,4	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2030	2032	AGC	108;109;109	A;G,A;C	71;73,1;75	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2533	85.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2048	2050	CCG	80;78;78	C,G;C,T;G,T	54,2;53,1;51,1	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	237	93.28	penA.l6.c30.ctg.2	496	1.7	0	.	p	.	0	G507fs	FSHIFT	1519	1519	G	254	254	C	ND	ND	ND	.	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	152	100.0	penA.l6.c30.ctg.3	496	4.7	1	SNP	p	T483S	0	.	.	1447	1449	C	1	1	C	5	C	1	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	152	100.0	penA.l6.c30.ctg.3	496	4.7	1	SNP	p	A501V	0	.	.	1501	1503	GCG	53	55	GCG	11;11;11	G;C;G	4;4;4	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	527	1170	penA	1746	152	100.0	penA.l6.c30.ctg.3	496	4.7	1	SNP	p	A501P	0	.	.	1501	1503	GCG	53	55	GCG	11;11;11	G;C;G	4;4;4	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1640	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	2909	103.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1390	1392	CCG	112;112;114	C;C;G,C	72;75;70,2	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	458	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1713	49.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	402	402	C	40	C	27	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	552	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1919	54.3	0	.	p	.	0	G252E	NONSYN	754	756	GGA	1150	1152	GAA	84;84;85	G,T;A;A	54,1;55;56	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	552	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1919	54.3	1	SNP	p	G120K	1	.	.	358	360	AAG	754	756	AAG	92;92;93	A;A;G,A	63;63;63,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	552	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1919	54.3	1	SNP	p	N121D	0	.	.	361	363	AAC	757	759	AAC	93;92;94	A;A;C	64;63;63	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	552	porB1b	1038	1038	99.9	porB1b.l15.c17.ctg.1	1919	54.3	1	SNP	p	A121N	1	.	.	361	363	AAC	757	759	AAC	93;92;94	A;A;C	64;63;63	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1850	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5024	71.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	142	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1225	23.8	1	SNP	p	V57M	1	.	.	169	171	ATG	710	712	ATG	57;57;57	A;T;G	39;39;39	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
